



MOREPEN



Date: 08/09/2025

To,

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Symbol: MOREPENLAB

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Scrip Code: 500288

Subject: Joint venture agreement executed between the subsidiary company and others

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir/ Madam,

This is to inform you that Morepen Medipath Limited (*formerly known as Morepen Medtech Limited*), a subsidiary of the company, has executed a joint venture agreement with Bimedical FZE, to form a joint venture company.

The disclosures pursuant to SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated 31st December 2024, is enclosed herewith as **Annexure**.

The information of execution of agreement was received to the company today at 12:31 p.m.

Thanking you,

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava
Company Secretary
F-12148

Encl.: a/a.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com



MOREPEN



Annexure

Disclosure under Regulations 30 of the SEBI LODR Regulations, read with circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024.

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.	<p>Pursuant to the Joint Venture Agreement entered into between Morepen Medipath Limited (“MML”), a subsidiary of the company, and Bimedical FZE, a UAE based entity, a new joint venture company (“JVC”) will be incorporated; the name and date of incorporation will be intimated in due course.</p> <p>Size: Authorised and paid capital are yet to be decided.</p> <p>Turnover: Not applicable</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>The proposed JVC will be related party of the company.</p> <p>The promoter/ promoter group of the company, do not have any interest in the proposed JVC, except as a members of MML.</p>
c)	Industry to which the entity being acquired belongs	Medical devices.
d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The proposed JVC will carry on the business of manufacturing, trading and selling of medical devices related products.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
f)	Indicative time period for completion of the acquisition	Not applicable
g)	Consideration - whether cash consideration or share swap or any other form and details of the same.	Cash

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com



h)	Cost of acquisition and/or the price at which the shares are acquired	MLL and Bimedical FZE, will contribute in the ratio of 50:50 in the share capital of the proposed JVC.
i)	Percentage of shareholding / control acquired and / or number of shares acquired.	The MLL will acquire 50% shareholding in the proposed JVC. The company will indirectly hold 30% shares on the proposed JCV through MLL.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	The proposed JVC will carry on the business of manufacturing, trading and selling of medical devices products. Date of incorporation: To be incorporated History of last 3 years' turnover: Not applicable Country of incorporation: India

Disclosures pursuant to SEBI Circular no. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated 31st December 2024.

Sr. No.	Particulars	Details
i)	Name of the entity, date & country of incorporation, etc.;	Refer point (a) and (j), above.
ii)	Name of holding company of the incorporated company and relation with the listed entity;	There will be no holding company of the proposed JVC. However, MML, a subsidiary of the company, will hold 50% in the proposed JVC.
iii)	Industry to which the entity being incorporated belongs;	Refer point (c), above.
iv)	Brief background about the entity incorporated in terms of products / line of business;	Refer point (d), above.
v)	Brief details of any governmental or regulatory approvals required for the incorporation;	Not applicable
vi)	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash
vii)	Cost of subscription / price at which the shares are subscribed;	Refer point (h), above.
viii)	Percentage of shareholding / control by the listed entity and / or number of shares allotted.	Refer point (i), above.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com